LIQUIDIA CORPORATION (LQDA) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $89.00K; Additional Paid in CapitalUSD $693.75M; Retained Earnings (Accumulated Deficit)USD $-498.73M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $88.00K; Additional Paid in CapitalUSD $681.94M; Retained Earnings (Accumulated Deficit)USD $-573.45M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $87.00K; Additional Paid in CapitalUSD $670.97M; Retained Earnings (Accumulated Deficit)USD $-626.31M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $87.00K; Additional Paid in CapitalUSD $662.83M; Retained Earnings (Accumulated Deficit)USD $-640.87M.
LIQUIDIA CORPORATION Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $89.00K | $693.75M | $-498.73M | $195.11M | 3 month · $10.37M | (m) |
| 2026-03-31 | $0.00 | $88.00K | $681.94M | $-573.45M | $108.58M | 3 month · $9.22M | (m) |
| 2025-12-31 | $0.00 | $87.00K | $670.97M | $-626.31M | $44.75M | 12 month · $29.47M | (m) |
| 2025-09-30 | $0.00 | $87.00K | $662.83M | $-640.87M | $22.05M | 3 month · $7.90M | (m) |
| 2025-06-30 | $0.00 | $86.00K | $652.44M | $-637.34M | $15.19M | 3 month · $6.93M | (m) |
| 2025-03-31 | $0.00 | $85.00K | $645.38M | $-595.76M | $49.71M | 3 month · $7.44M | (m) |
| 2024-12-31 | $0.00 | $85.00K | $636.68M | $-557.39M | $79.38M | 12 month · $18.81M | (m) |
| 2024-09-30 | $0.00 | $85.00K | $631.56M | $-518.88M | $112.76M | 3 month · $4.88M | (m) |
| 2024-06-30 | $0.00 | $76.00K | $560.61M | $-487.85M | $72.84M | 3 month · $4.37M | (m) |
| 2024-03-31 | $0.00 | $76.00K | $556.21M | $-459.18M | $97.11M | 3 month · $4.52M | (m) |
| 2023-12-31 | $0.00 | $69.00K | $476.32M | $-429.10M | $47.29M | 12 month · $10.09M | (m) |
| 2023-09-30 | $0.00 | $65.00K | $449.59M | $-401.65M | $48.01M | 3 month · $2.49M | (m) |
| 2023-06-30 | $0.00 | $65.00K | $446.45M | $-385.86M | $60.66M | 3 month · $2.50M | (m) |
| 2023-03-31 | $0.00 | $65.00K | $443.92M | $-362.34M | $81.64M | 3 month · $2.55M | (m) |
| 2022-12-31 | $0.00 | $64.00K | $440.95M | $-350.60M | $90.42M | 12 month · $9.30M | 12 month · $1.32M |
| 2022-09-30 | $0.00 | $64.00K | $439.03M | $-344.06M | $95.03M | 3 month · $1.65M | (m) |
| 2022-06-30 | $0.00 | $64.00K | $437.01M | $-334.97M | $102.11M | 3 month · $1.70M | (m) |
| 2022-03-31 | $0.00 | $53.00K | $380.86M | $-325.52M | $55.39M | 3 month · $4.13M | 3 month · $1.32M |
| 2021-12-31 | $0.00 | $52.00K | $374.79M | $-309.58M | $65.27M | 12 month · $6.75M | 12 month · $261.00K |
| 2021-09-30 | $0.00 | $51.98K | $370.93M | $-298.02M | $72.96M | 3 month · $1.22M | (m) |
| 2021-06-30 | $0.00 | $51.98K | $369.71M | $-290.74M | $79.02M | 3 month · $953.00K | (m) |
| 2021-03-31 | $0.00 | $43.35K | $347.05M | $-284.19M | $62.91M | 3 month · $745.00K | 3 month · $261.00K |
| 2020-12-31 | $0.00 | $43.34K | $346.04M | $-275.00M | $71.09M | 12 month · $3.95M | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | $65.28M | 3 month · $1.08M | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | $8.87M | 3 month · $988.12K | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | $21.77M | 3 month · $878.96K | (m) |
| 2019-12-31 | $0.00 | $28.23K | $250.16M | $-215.24M | $34.95M | 12 month · $3.38M | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | $18.69M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |